Primary results from a new clinical trial show that a discrete subset of patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) demonstrated especially ...
Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback